Vanderbilt University School of Medicine

Penson, David F , MD, MPH
Director Center for Surgical Quality and Outcomes Research
Professor of Urologic Surgery
Paul V. Hamilton, M.D. and Virginia E. Howd Chair in Urologic Oncology
Professor of Medicine

Lab Url: N/A

Phone Number: 615-343-1529

Email Address:david.penson@vanderbilt.edu

Penson, David's picture

Office Address   Mailing Address

2525 West End Avenue, Suite 1200

37203-1738


Clinical Research Description
My primary research interest has been in using population-based cohorts and assessing patient-reported outcomes in conditions treated with surgical procedures, specifically prostate cancer. My additional interests include (but are not limited to) cost-effectiveness analyses, exploring disparities in access and quality of care across numerous surgical conditions. I also maintain a focus on improving clinical decision-making.

Publications
Anderson, CB, Morgan, TM, Kappa, S, Moore, D, Clark, PE, Davis, R, Penson, DF, Barocas, DA, Smith, JA, Cookson, MS, Chang, SS. Ureteroenteric anastomotic strictures after radical cystectomy-does operative approach matter. J Urol, 189(2), 541-7, 2013.

Anderson, CB, Penson, DF, Ni, S, Makarov, DV, Barocas, DA. Centralization of radical prostatectomy in the United States. J Urol, 189(2), 500-6, 2013.

Barocas, DA, Grubb, R, Black, A, Penson, DF, Fowke, JH, Andriole, G, Crawford, ED. Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the Prostate, Lung, Colorectal, and Ovarian cancer screening trial. Cancer, 119(12), 2223-9, 2013.

Kaffenberger, SD, Keegan, KA, Bansal, NK, Morgan, TM, Tang, DH, Barocas, DA, Penson, DF, Davis, R, Clark, PE, Chang, SS, Cookson, MS, Herrell, SD, Smith, JA. Salvage robotic assisted laparoscopic radical prostatectomy: a single institution, 5-year experience. J Urol, 189(2), 507-13, 2013.

Penson, DF. Editorial comment. J Urol, 190(2), 398, 2013.

Penson, DF. Post-prostatectomy Incontinence and Pelvic Floor Muscle Training: A Defining Problem. Eur Urol, , , 2013.

Penson, DF. Time to raise the bar in localised prostate cancer. BJU Int, 112(3), 278, 2013.

Penson, DF. Capsule Commentary on Shahinian et al.: Patterns of Bone Mineral Density Testing in Men Receiving Androgen Deprivation for Prostate Cancer. J Gen Intern Med, , , 2013.

Resnick, MJ, Guzzo, TJ, Cowan, JE, Knight, SJ, Carroll, PR, Penson, DF. Factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). BJU Int, 111(2), 213-20, 2013.

Resnick, MJ, Koyama, T, Fan, KH, Albertsen, PC, Goodman, M, Hamilton, AS, Hoffman, RM, Potosky, AL, Stanford, JL, Stroup, AM, Van Horn, RL, Penson, DF. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med, 368(5), 436-45, 2013.

Reynolds, WS, Dmochowski, RR, Lai, J, Saigal, C, Penson, DF, , . Patterns and predictors of urodynamics use in the United States. J Urol, 189(5), 1791-6, 2013.

Reynolds, WS, Gold, KP, Ni, S, Kaufman, MR, Dmochowski, RR, Penson, DF. Immediate effects of the initial FDA notification on the use of surgical mesh for pelvic organ prolapse surgery in medicare beneficiaries. Neurourol Urodyn, 32(4), 330-5, 2013.

Barocas, DA, Gray, DT, Fowke, JH, Mercaldo, ND, Blume, JD, Chang, SS, Cookson, MS, Smith, JA, Penson, DF. Racial variation in the quality of surgical care for prostate cancer. J Urol, 188(4), 1279-85, 2012.

Fowke, JH, Motley, SS, Concepcion, RS, Penson, DF, Barocas, DA. Obesity, body composition, and prostate cancer. BMC Cancer, 12, 23, 2012. PMCID:3292483

Kavitt, RT, Penson, DF, Vaezi, MF. Eosinophilic esophagitis: dilate or medicate? A cost analysis model of the choice of initial therapy. Dis Esophagus, , , 2012.

Keegan, KA, Penson, DF. The patient protection and affordable care act: The impact on urologic cancer care. Urol Oncol, , , 2012.

Makarov, DV, Desai, RA, Yu, JB, Sharma, R, Abraham, N, Albertsen, PC, Penson, DF, Gross, CP. The population level prevalence and correlates of appropriate and inappropriate imaging to stage incident prostate cancer in the medicare population. J Urol, 187(1), 97-102, 2012. PMCID:3292483

Morgan, TM, Barocas, DA, Keegan, KA, Cookson, MS, Chang, SS, Ni, S, Clark, PE, Smith, JA, Penson, DF. Volume outcomes of cystectomy--is it the surgeon or the setting. J Urol, 188(6), 2139-44, 2012.

Morgan, TM, Barocas, DA, Penson, DF, Chang, SS, Ni, S, Clark, PE, Smith, JA, Cookson, MS. Lymph node yield at radical cystectomy predicts mortality in node-negative and not node-positive patients. Urology, 80(3), 632-40, 2012.

Patel, SG, Penson, DF, Pabla, B, Clark, PE, Cookson, MS, Chang, SS, Herrell, SD, Smith, JA, Barocas, DA. National trends in the use of partial nephrectomy: a rising tide that has not lifted all boats. J Urol, 187(3), 816-21, 2012. PMCID:3292483

Penson, DF. Re: Satisfaction profiles in men using intracavernosal injection therapy. J Urol, 187(1), 245-6, 2012. PMCID:3292483

Penson, DF. Re: today''s ''meaningful use'' standard for medication orders by hospitals may save few lives; later stages may do more. J Urol, 187(2), 646, 2012. PMCID:3292483

Penson, DF. Re: higher fees paid to us physicians drive higher spending for physician services compared to other countries. J Urol, 187(2), 647-8, 2012. PMCID:3292483

Penson, DF. Re: US physician practices versus Canadians: spending nearly four times as much money interacting with payers. J Urol, 187(2), 648, 2012. PMCID:3292483

Penson, DF. Re: How Well Informed are Women Who Undergo Urodynamic Testing. J Urol, 187(3), 965, 2012.

Penson, DF. Re: physician documentation of fluoroscopy time in voiding cystourethrography reports correlates with lower fluoroscopy times: a surrogate marker of patient radiation exposure. J Urol, 187(3), 965-6, 2012.

Penson, DF. Re: Urologist Compliance With AUA Best Practice Guidelines for Benign Prostatic Hyperplasia in Medicare Population. J Urol, 187(3), 966-7, 2012.

Penson, DF. Editorial Comments. J Urol, , , 2012.

Penson, DF. Re: Fifteen-year trend in the use of male reproductive surgery: analysis of the healthcare cost and utilization project data. J Urol, 187(1), 246, 2012. PMCID:3292483

Penson, DF. Factors influencing patients'' acceptance and adherence to active surveillance. J Natl Cancer Inst Monogr, 2012(45), 207-12, 2012.

Resnick, MJ, Penson, DF. Quality of life with advanced metastatic prostate cancer. Urol Clin North Am, 39(4), 505-15, 2012.

Wein, AJ, Penson, DF. Re: What patients think: patient-reported outcomes of retropubic versus trans-obturator mid-urethral slings for urodynamic stress incontinence--a multi-centre randomised controlled trial. J Urol, 187(1), 203-5, 2012.

Wein, AJ, Penson, DF. Re: Transobturator TVT-O versus retropubic TVT: results of a multicenter randomized controlled trial at 24 months follow-up. J Urol, 187(1), 203-4, 2012.

Wein, AJ, Penson, DF. Re: Retropubic versus transobturator midurethral slings for stress incontinence. J Urol, 187(1), 202-4, 2012. PMCID:3292483

Barocas, DA, Motley, S, Cookson, MS, Chang, SS, Penson, DF, Dai, Q, Milne, G, Roberts, LJ, Morrow, J, Concepcion, RS, Smith, JA, Fowke, JH. Oxidative Stress Measured by Urine F2-Isoprostane Level is Associated With Prostate Cancer. J Urol, , , 2011.

Birkhahn, M, Penson, DF, Cai, J, Groshen, S, Stein, JP, Lieskovsky, G, Skinner, DG, Cote, RJ. Long-term outcome in patients with a Gleason score a??6 prostate cancer treated by radical prostatectomy. BJU Int, , , 2011.

Davies, JD, Aghazadeh, MA, Phillips, S, Salem, S, Chang, SS, Clark, PE, Cookson, MS, Davis, R, Herrell, SD, Penson, DF, Smith, JA, Barocas, DA. Prostate size as a predictor of Gleason score upgrading in patients with low risk prostate cancer. J Urol, 186(6), 2221-7, 2011. PMCID:3292483

Epplein, M, Zheng, Y, Zheng, W, Chen, Z, Gu, K, Penson, D, Lu, W, Shu, XO. Quality of life after breast cancer diagnosis and survival. J Clin Oncol, 29(4), 406-12, 2011.

Fowke, JH, Munro, H, Signorello, LB, Blot, WJ, Penson, DF, , . Association between socioeconomic status (SES) and lower urinary tract symptom (LUTS) severity among black and white men. J Gen Intern Med, 26(11), 1305-10, 2011. PMCID:3292483

Makarov, DV, Yu, JB, Desai, RA, Penson, DF, Gross, CP. The association between diffusion of the surgical robot and radical prostatectomy rates. Med Care, 49(4), 333-9, 2011.

Maripuri, S, Penson, DF, Ikizler, TA, Cavanaugh, KL. Outpatient versus inpatient observation after percutaneous native kidney biopsy: a cost minimization study. Am J Nephrol, 34(1), 64-70, 2011. PMCID:3123742

McVary, KT, Roehrborn, CG, Avins, AL, Barry, MJ, Bruskewitz, RC, Donnell, RF, Foster, HE, Gonzalez, CM, Kaplan, SA, Penson, DF, Ulchaker, JC, Wei, JT. Update on AUA Guideline on the Management of Benign Prostatic Hyperplasia. J Urol, 185(5), 1793-803, 2011.

Morgan, TM, Barocas, DA, Chang, SS, Phillips, SE, Salem, S, Clark, PE, Penson, DF, Smith, JA, Cookson, MS. The relationship between perioperative blood transfusion and overall mortality in patients undergoing radical cystectomy for bladder cancer. Urol Oncol, , , 2011. PMCID:3292483

Morgan, TM, Keegan, KA, Barocas, DA, Ruhotina, N, Phillips, SE, Chang, SS, Penson, DF, Clark, PE, Smith, JA, Cookson, MS. Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy. J Urol, 186(3), 829-34, 2011. PMCID:3292483

Padmanabhan, P, Scarpero, HM, Milam, DF, Dmochowski, RR, Penson, DF. Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity. World J Urol, 29(1), 51-7, 2011.

Penson, DF. Treatment for postprostatectomy incontinence: is this as good as it gets. JAMA, 305(2), 197-8, 2011.

Penson, DF. Re: Treatment Outcomes and Resource Use of Patients With Neurogenic Detrusor Overactivity Receiving Botulinum Toxin A (BOTOX) Therapy in Germany. J Urol, 185(4), 1383-4, 2011. PMCID:3292483

Penson, DF. Re: can pelvic floor muscle training reverse pelvic organ prolapse and reduce prolapse symptoms? An assessor-blinded, randomized, controlled trial. J Urol, 185(4), 1383, 2011. PMCID:3292483

Penson, DF. Re: Complementary and Alternative Medicine (CAM) Use in Women With Pelvic Floor Disorders: A Cohort Study. J Urol, 185(4), 1382-3, 2011. PMCID:3292483

Penson, DF. Re: Assessment of quality of cancer-related follow-up care from the cancer survivor''s perspective. J Urol, 186(6), 2349, 2011. PMCID:3292483

Penson, DF. Re: Validating the patient safety indicators in the Veterans Health Administration: are they ready for prime time. J Urol, 186(6), 2347-8, 2011. PMCID:3292483

Penson, DF, Lange, PH. Systemic therapy and the urologic oncologist: a unique opportunity for the specialty to provide comprehensive care that ultimately benefits the patient. Urol Oncol, 30(4 Suppl), S2-4, 2011.

Penson, DF, Munro, HM, Signorello, LB, Blot, WJ, Fowke, JH, , . Obesity, physical activity and lower urinary tract symptoms: results from the Southern Community Cohort Study. J Urol, 186(6), 2316-22, 2011. PMCID:3292483

Reynolds, WS, Dmochowski, RR, Penson, DF. Epidemiology of stress urinary incontinence in women. Curr Urol Rep, 12(5), 370-6, 2011. PMCID:3292483

Wessells, H, Penson, DF, Cleary, P, Rutledge, BN, Lachin, JM, McVary, KT, Schade, DS, Sarma, AV, , . Effect of intensive glycemic therapy on erectile function in men with type 1 diabetes. J Urol, 185(5), 1828-34, 2011.

Zeliadt, SB, Penson, DF, Moinpour, CM, Blough, DK, Fedorenko, CR, Hall, IJ, Smith, JL, Ekwueme, DU, Thompson, IM, Keane, TE, Ramsey, SD. Provider and partner interactions in the treatment decision-making process for newly diagnosed localized prostate cancer. BJU Int, , , 2011.

Barocas, DA, Penson, DF. Racial variation in the pattern and quality of care for prostate cancer in the USA: mind the gap. BJU Int, 106(3), 322-8, 2010.

Hadley, J, Yabroff, KR, Barrett, MJ, Penson, DF, Saigal, CS, Potosky, AL. Comparative Effectiveness of Prostate Cancer Treatments: Evaluating Statistical Adjustments for Confounding in Observational Data. J Natl Cancer Inst, , , 2010.

Hamilton, AS, Albertsen, PC, Johnson, TK, Hoffman, R, Morrell, D, Deapen, D, Penson, DF. Trends in the treatment of localized prostate cancer using supplemented cancer registry data. BJU Int, , , 2010.

Huang, GJ, Sadetsky, N, Penson, DF. Health related quality of life for men treated for localized prostate cancer with long-term followup. J Urol, 183(6), 2206-12, 2010.

Kantoff, PW, Higano, CS, Shore, ND, Berger, ER, Small, EJ, Penson, DF, Redfern, CH, Ferrari, AC, Dreicer, R, Sims, RB, Xu, Y, Frohlich, MW, Schellhammer, PF, , . Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med, 363(5), 411-22, 2010.

Makarov, DV, Loeb, S, Landman, AB, Nielsen, ME, Gross, CP, Leslie, DL, Penson, DF, Desai, RA. Regional variation in total cost per radical prostatectomy in the healthcare cost and utilization project nationwide inpatient sample database. J Urol, 183(4), 1504-9, 2010.

Moses, KA, Paciorek, AT, Penson, DF, Carroll, PR, Master, VA. Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE. J Clin Oncol, 28(6), 1069-74, 2010.

Ramsey, SD, Zeliadt, SB, Arora, NK, Blough, DK, Penson, DF, Oakley-Girvan, I, Hamilton, AS, Van Den Eeden, SK, Fedorenko, CR, Potosky, AL. Unanticipated and Underappreciated Outcomes During Management of Local Stage Prostate Cancer: A Prospective Survey. J Urol, , , 2010.

Ramsey, SD, Zeliadt, SB, Fedorenko, CR, Blough, DK, Moinpour, CM, Hall, IJ, Smith, JL, Ekwueme, DU, Fairweather, ME, Thompson, IM, Keane, TE, Penson, DF. Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinions. World J Urol, , , 2010.

Stimson, CJ, Dmochowski, R, Penson, DF. Health care reform 2010: a fresh view on tort reform. J Urol, 184(5), 1840-6, 2010.

Thong, MS, Van De Poll-Franse, L, Hoffman, RM, Albertsen, PC, Hamilton, AS, Stanford, JL, Penson, DF. Diabetes mellitus and health-related quality of life in prostate cancer: 5-year results from the Prostate Cancer Outcomes Study. BJU Int, , , 2010.

Zeliadt, SB, Moinpour, CM, Blough, DK, Penson, DF, Hall, IJ, Smith, JL, Ekwueme, DU, Thompson, IM, Keane, TE, Ramsey, SD. Preliminary treatment considerations among men with newly diagnosed prostate cancer. Am J Manag Care, 16(5), e121-30, 2010.

Bruins, HM, Huang, GJ, Cai, J, Skinner, DG, Stein, JP, Penson, DF. Clinical outcomes and recurrence predictors of lymph node positive urothelial cancer after cystectomy. J Urol, 182(5), 2182-7, 2009.

Makarov, DV, Penson, DF. Prostate cancer: quality of life after radiation and androgen deprivation. Nat Rev Urol, 6(9), 477-8, 2009.

Nichol, MB, Knight, TK, Wu, J, Barron, R, Penson, DF. Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia. J Urol, 181(5), 2214-21; discussion 2221-2, 2009.

Penson, DF. Active surveillance: not your father''s watchful waiting. Oncology (Williston Park), 23(11), 980, 982, 2009.

Penson, DF, Wessells, H, Cleary, P, Rutledge, BN, , . Sexual dysfunction and symptom impact in men with long-standing type 1 diabetes in the DCCT/EDIC cohort. J Sex Med, 6(7), 1969-78, 2009.

Ramsey, SD, Zeliadt, SB, Arora, NK, Potosky, AL, Blough, DK, Hamilton, AS, Van Den Eeden, SK, Oakley-Girvan, I, Penson, DF. Access to information sources and treatment considerations among men with local stage prostate cancer. Urology, 74(3), 509-15, 2009. PMCID:2748115

Stein, JP, Penson, DF, Lee, C, Cai, J, Miranda, G, Skinner, DG. Long-term oncological outcomes in women undergoing radical cystectomy and orthotopic diversion for bladder cancer. J Urol, 181(5), 2052-8; discussion 2058-9, 2009.

Zeliadt, SB, Ramsey, SD, Van Den Eeden, SK, Hamilton, AS, Oakley-Girvan, I, Penson, DF, Fairweather, ME, Arora, NK, Potosky, AL. Patient Recruitment Methods to Evaluate Treatment Decision Making for Localized Prostate Cancer. Am J Clin Oncol, , , 2009.

Etzioni, R, Gulati, R, Falcon, S, Penson, DF. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Med Decis Making, 28(3), 323-31, 2008.

Etzioni, R, Tsodikov, A, Mariotto, A, Szabo, A, Falcon, S, Wegelin, J, DiTommaso, D, Karnofski, K, Gulati, R, Penson, DF, Feuer, E. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control, 19(2), 175-81, 2008.

Huang, GJ, Hamilton, AS, Lo, M, Stein, JP, Penson, DF. Predictors of intravesical therapy for nonmuscle invasive bladder cancer: results from the surveillance, epidemiology and end results program 2003 patterns of care project. J Urol, 180(2), 520-4; discussion 524, 2008.

Huang, GJ, Penson, DF. Internet health resources and the cancer patient. Cancer Invest, 26(2), 202-7, 2008.

Lloyd, A, Penson, D, Dewilde, S, Kleinman, L. Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer. Prostate Cancer Prostatic Dis, 11(2), 153-9, 2008.

Penson, DF, McLerran, D, Feng, Z, Li, L, Albertsen, PC, Gilliland, FD, Hamilton, A, Hoffman, RM, Stephenson, RA, Potosky, AL, Stanford, JL. 5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. J Urol, 179(5 Suppl), S40-4, 2008.

Penson, DF, Rossignol, M, Sartor, AO, Scardino, PT, Abenhaim, LL. Prostate cancer: epidemiology and health-related quality of life. Urology, 72(6 Suppl), S3-11, 2008.

Stein, JP, Penson, DF. Invasive T1 bladder cancer: indications and rationale for radical cystectomy. BJU Int, 102(3), 270-5, 2008.

Stein, JP, Penson, DF. The invasive T1 bladder tumor: contemporary issues and rationale for radical cystectomy. Curr Urol Rep, 9(3), 179-81, 2008.

Albertsen, PC, Hanley, JA, Penson, DF, Barrows, G, Fine, J. 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. J Urol, 177(3), 932-6, 2007.

Gonzalez, CM, Penson, D, Kosiak, B, Dupree, J, Clemens, JQ. Pay for performance: rationale and potential implications for urology. J Urol, 178(2), 402-8, 2007.

Graff, JN, Mori, M, Li, H, Garzotto, M, Penson, D, Potosky, AL, Beer, TM. Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study. J Urol, 177(4), 1307-12, 2007.

Ramsey, SD, Zeliadt, SB, Hall, IJ, Ekwueme, DU, Penson, DF. On the importance of race, socioeconomic status and comorbidity when evaluating quality of life in men with prostate cancer. J Urol, 177(6), 1992-9, 2007.

Singer, EA, Penson, DF, Palapattu, GS. PSA screening and elderly men. JAMA, 297(9), 949; author reply 949-50, 2007.

Stein, JP, Penson, DF, Cai, J, Miranda, G, Skinner, EC, Dunn, MA, Groshen, S, Lieskovsky, G, Skinner, DG. Radical cystectomy with extended lymphadenectomy: evaluating separate package versus en bloc submission for node positive bladder cancer. J Urol, 177(3), 876-81; discussion 881-2, 2007.

Stein, JP, Penson, DF, Wu, SD, Skinner, DG. Pathological guidelines for orthotopic urinary diversion in women with bladder cancer: a review of the literature. J Urol, 178(3 Pt 1), 756-60, 2007.

Zeliadt, SB, Etzioni, R, Ramsey, SD, Penson, DF, Potosky, AL. Trends in treatment costs for localized prostate cancer: the healthy screenee effect. Med Care, 45(2), 154-9, 2007.

Zeliadt, SB, Penson, DF. Pharmacoeconomics of available treatment options for metastatic prostate cancer. Pharmacoeconomics, 25(4), 309-27, 2007.

Black, PC, Penson, DF. Prostate cancer on the Internet--information or misinformation. J Urol, 175(5), 1836-42; discussion 1842, 2006.

Latini, DM, Penson, DF, Wallace, KL, Lubeck, DP, Lue, TF. Clinical and psychosocial characteristics of men with erectile dysfunction: baseline data from ExCEED. J Sex Med, 3(6), 1059-67, 2006.

Latini, DM, Penson, DF, Wallace, KL, Lubeck, DP, Lue, TF. Longitudinal differences in psychological outcomes for men with erectile dysfunction: results from ExCEED. J Sex Med, 3(6), 1068-76, 2006.

Penson, D, Moul, J, Gandhi, S, Newling, D. Use of prostate-specific antigen in the follow-up of patients with localized prostate cancer: results of a nationwide survey of urologists. Urology, 68(1), 80-4, 2006.

Sanderson, KM, Penson, DF, Cai, J, Groshen, S, Stein, JP, Lieskovsky, G, Skinner, DG. Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. J Urol, 176(5), 2025-31; discussion 2031-2, 2006.

Yang, CC, Porter, MP, Penson, DF. Comparison of the International Index of Erectile Function erectile domain scores and nocturnal penile tumescence and rigidity measurements: does one predict the other. BJU Int, 98(1), 105-9; discussion 109, 2006.

Zeliadt, SB, Potosky, AL, Penson, DF, Etzioni, R. Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys, 66(2), 395-402, 2006.

Albertsen, PC, Hanley, JA, Barrows, GH, Penson, DF, Kowalczyk, PD, Sanders, MM, Fine, J. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst, 97(17), 1248-53, 2005.

Penson, DF, McLerran, D, Feng, Z, Li, L, Albertsen, PC, Gilliland, FD, Hamilton, A, Hoffman, RM, Stephenson, RA, Potosky, AL, Stanford, JL. 5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. J Urol, 173(5), 1701-5, 2005.

Penson, DF, Ramsey, S, Veenstra, D, Clarke, L, Gandhi, S, Hirsch, M. The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer. J Urol, 174(2), 547-52; discussion 552, 2005.

Porter, MP, Penson, DF. Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature. J Urol, 173(4), 1318-22, 2005.

Ramsey, S, Veenstra, D, Clarke, L, Gandhi, S, Hirsch, M, Penson, D. Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide. Urology, 66(4), 835-9, 2005.

Zeliadt, SB, Etzioni, RD, Penson, DF, Thompson, IM, Ramsey, SD. Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. Am J Med, 118(8), 850-7, 2005.

Albertsen, PC, Hanley, JA, Penson, DF, Fine, J. Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. J Urol, 171(6 Pt 1), 2221-5, 2004.

Inoue, LY, Etzioni, R, Slate, EH, Morrell, C, Penson, DF. Combining longitudinal studies of PSA. Biostatistics, 5(3), 483-500, 2004.

Johnson, TK, Gilliland, FD, Hoffman, RM, Deapen, D, Penson, DF, Stanford, JL, Albertsen, PC, Hamilton, AS. Racial/Ethnic differences in functional outcomes in the 5 years after diagnosis of localized prostate cancer. J Clin Oncol, 22(20), 4193-201, 2004.

Neuhouser, ML, Kristal, AR, Penson, DF. Steroid hormones and hormone-related genetic and lifestyle characteristics as risk factors for benign prostatic hyperplasia: review of epidemiologic literature. Urology, 64(2), 201-11, 2004.

Penson, DF, Moul, JW, Evans, CP, Doyle, JJ, Gandhi, S, Lamerato, L. The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. J Urol, 171(6 Pt 1), 2250-4, 2004.

Potosky, AL, Davis, WW, Hoffman, RM, Stanford, JL, Stephenson, RA, Penson, DF, Harlan, LC. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst, 96(18), 1358-67, 2004.

Rosenfeld, B, Roth, AJ, Gandhi, S, Penson, D. Differences in health-related quality of life of prostate cancer patients based on stage of cancer. Psychooncology, 13(11), 800-7, 2004.

Zeliadt, SB, Potosky, AL, Etzioni, R, Ramsey, SD, Penson, DF. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology, 64(6), 1171-6, 2004.

Latini, DM, Penson, DF, Lubeck, DP, Wallace, KL, Henning, JM, Lue, TF. Longitudinal differences in disease specific quality of life in men with erectile dysfunction: results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction study. J Urol, 169(4), 1437-42, 2003.

Penson, DF, Feng, Z, Kuniyuki, A, McClerran, D, Albertsen, PC, Deapen, D, Gilliland, F, Hoffman, R, Stephenson, RA, Potosky, AL, Stanford, JL. General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study. J Clin Oncol, 21(6), 1147-54, 2003.

Penson, DF, Latini, DM, Lubeck, DP, Wallace, K, Henning, JM, Lue, T. Is quality of life different for men with erectile dysfunction and prostate cancer compared to men with erectile dysfunction due to other causes? Results from the ExCEED data base. J Urol, 169(4), 1458-61, 2003.

Penson, DF, Latini, DM, Lubeck, DP, Wallace, KL, Henning, JM, Lue, TF, , . Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction (ExCEED) database. Diabetes Care, 26(4), 1093-9, 2003.

Plaskon, LA, Penson, DF, Vaughan, TL, Stanford, JL. Cigarette smoking and risk of prostate cancer in middle-aged men. Cancer Epidemiol Biomarkers Prev, 12(7), 604-9, 2003.

Zeliadt, SB, Penson, DF, Albertsen, PC, Concato, J, Etzioni, RD. Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis. Cancer, 98(3), 496-503, 2003.

Etzioni, R, Penson, DF, Legler, JM, di Tommaso, D, Boer, R, Gann, PH, Feuer, EJ. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst, 94(13), 981-90, 2002.

Latini, DM, Penson, DF, Colwell, HH, Lubeck, DP, Mehta, SS, Henning, JM, Lue, TF. Psychological impact of erectile dysfunction: validation of a new health related quality of life measure for patients with erectile dysfunction. J Urol, 168(5), 2086-91, 2002.

Penson, DF, Grossfeld, GD, Li, YP, Henning, JM, Lubeck, DP, Carroll, PR. How well does the Partin nomogram predict pathological stage after radical prostatectomy in a community based population? Results of the cancer of the prostate strategic urological research endeavor. J Urol, 167(4), 1653-7; discussion 1657-8, 2002.

Penson, DF, Paltiel, AD, Krumholz, HM, Palter, S. The cost-effectiveness of treatment for varicocele related infertility. J Urol, 168(6), 2490-4, 2002.

Penson, DF, Albertsen, PC, Nelson, PS, Barry, M, Stanford, JL. Determining cause of death in prostate cancer: are death certificates valid. J Natl Cancer Inst, 93(23), 1822-3, 2001.

Penson, DF, Schonfeld, WH, Flanders, SC, Henke, CJ, Warolin, KL, Carroll, PR, Litwin, MS. Relationship of first-year costs of treating localized prostate cancer to initial choice of therapy and stage at diagnosis: results from the CAPSURE database. Urology, 57(3), 499-503, 2001.

Penson, DF, Stoddard, ML, Pasta, DJ, Lubeck, DP, Flanders, SC, Litwin, MS. The association between socioeconomic status, health insurance coverage, and quality of life in men with prostate cancer. J Clin Epidemiol, 54(4), 350-8, 2001.

Corman, JM, Penson, DF, Hur, K, Khuri, SF, Daley, J, Henderson, W, Krieger, JN. Comparison of complications after radical and partial nephrectomy: results from the National Veterans Administration Surgical Quality Improvement Program. BJU Int, 86(7), 782-9, 2000.

Taneja, SS, Penson, DF, Epelbaum, A, Handler, T, Lepor, H. Does site specific labeling of sextant biopsy cores predict the site of extracapsular extension in radical prostatectomy surgical specimen. J Urol, 162(4), 1352-7; discussion 1357-8, 1999.

Penson, DF, Litwin, MS, Lubeck, DP, Flanders, S, Pasta, DJ, Carroll, PR. Transitions in health-related quality of life during the first nine months after diagnosis with prostate cancer. Prostate Cancer Prostatic Dis, 1(3), 134-143, 1998.

Penson, DF, Lugg, JA, Coyne, C, Sadeghi, F, Freedman, AL, Gonzalez-Cadavid, NF, Rajfer, J. Effect of cryptorchidism on testicular histology in a naturally cryptorchid animal model. J Urol, 158(5), 1978-82, 1997.

Penson, DF, Ng, C, Rajfer, J, Gonzalez-Cadavid, NF. Adrenal control of erectile function and nitric oxide synthase in the rat penis. Endocrinology, 138(9), 3925-32, 1997.

Lugg, JA, Penson, DF, Sadeghi, F, Petrie, B, Freedman, AL, Gonzalez-Cadavid, NF, Hikim, AS, Rajfer, J. Prevention of seminiferous tubular atrophy in a naturally cryptorchid rat model by early surgical intervention. J Androl, 17(6), 726-32, 1996.


Postdoctoral Position Available
N/A

Postdoctoral Position Details
N/A

Updated Date
07/17/2013



Vanderbilt University is committed to principles of equal opportunity and affirmative action.
Copyright 2008 Vanderbilt University School of Medicine
The office of Biomedical Research Education & Training All rights reserved.
For questions or problems concerning this page, please submit a help ticket.